Sanofi-Aventis (France) Gets Non-Approvable Letter From US FDA For Dronedarone

August 31, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

PARIS, Aug 31 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) said on Thursday that U.S health authorities had rejected its application for dronedarone, a heart arrythmia treatment branded as Multaq.

>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Food and Drug Administration (FDA) Sanofi (France)